Do Not Initiate Upadacitinib in Patients with Active Gastric Ulcer
Upadacitinib should not be started in a patient with an active gastric ulcer due to the risk of gastrointestinal perforation and the need to first address the active ulcerative disease. The gastric ulcer must be treated and healed before considering JAK inhibitor therapy.
Rationale Based on Safety Evidence
Gastrointestinal Perforation Risk
The FDA drug label for upadacitinib does not explicitly list active peptic ulcer disease as a contraindication, but JAK inhibitor consensus guidelines and safety data raise significant concerns 1:
Gastrointestinal perforations have been reported with JAK inhibitors, particularly at higher doses. In the upadacitinib phase III program for rheumatoid arthritis, rates of GI perforation were higher with the 30 mg dose 2.
The 2021 consensus statement on JAK inhibitors emphasizes that patients with severe active infections or chronic conditions should be carefully evaluated before initiating therapy 1.
While a systematic review found no statistically significant increase in GI perforation risk with upadacitinib compared to conventional DMARDs in pooled analysis (OR = 4.49,95% CI 0.56 to 35.93), the wide confidence interval and low event rates make this reassuring only for patients without pre-existing GI pathology 3.
Clinical Algorithm for Decision-Making
Step 1: Assess the gastric ulcer status
- Active ulcer with symptoms (pain, bleeding, or recent diagnosis on endoscopy) = absolute contraindication to starting upadacitinib
- Healed ulcer with appropriate treatment = may proceed with caution
Step 2: If ulcer is active, initiate appropriate treatment
- Proton pump inhibitor therapy (standard dose for 8-12 weeks)
- Helicobacter pylori eradication if positive
- Discontinue NSAIDs if being used
- Document healing with repeat endoscopy if clinically indicated
Step 3: Once ulcer is healed, reassess RA treatment needs
- Consider upadacitinib 15 mg once daily (the approved dose for RA) 4, 5
- Continue PPI therapy as gastroprotection during JAK inhibitor use
- Monitor for GI symptoms closely during the first 3-6 months
Additional Safety Considerations
Pre-treatment Requirements Before Starting Upadacitinib
Per consensus guidelines and FDA labeling 1, 5:
- Complete blood count with differential (baseline and at 1 and 3 months)
- Liver function tests (AST/ALT at baseline and periodically)
- Tuberculosis screening (per national guidelines)
- Hepatitis B and C testing
- Lipid panel (at 12 weeks post-initiation)
- Vaccination status update (particularly herpes zoster vaccine before starting, as rates of herpes zoster are increased with upadacitinib compared to TNF inhibitors) 2, 6
Contraindications to Upadacitinib
Absolute contraindications include 1, 5:
- Severe active infections (including tuberculosis)
- Current malignancies
- Severe hepatic impairment (Child-Pugh C)
- Pregnancy and lactation
- Recurrent venous thromboembolism (unless anticoagulated)
Common Pitfalls to Avoid
Do not assume that because NSAIDs cause ulcers, JAK inhibitors are safe alternatives in active ulcer disease - both can compromise GI mucosal integrity through different mechanisms.
Do not start upadacitinib simply because the patient failed methotrexate - ensure all safety screening is complete and active comorbidities are addressed first 7, 8.
Do not use upadacitinib as first-line therapy in treatment-naïve RA patients with active ulcer disease - guidelines recommend starting with conventional synthetic DMARDs (methotrexate, sulfasalazine, or leflunomide) which have better-established GI safety profiles 7, 4.
When Upadacitinib Can Be Considered
Once the gastric ulcer is documented as healed:
- Upadacitinib 15 mg once daily is appropriate for RA patients who have inadequate response to methotrexate or other conventional DMARDs 8, 4
- It has demonstrated superior efficacy to adalimumab in head-to-head trials for ACR responses 4, 9
- Real-world data shows 73% DAS28-CRP remission rates at 3 months 10
- Maintain PPI therapy indefinitely as gastroprotection
- Monitor for new GI symptoms, particularly abdominal pain that could signal perforation